Wipro, BPCL, Paytm, Aurobindo Pharma: Stocks to watch on Monday

Stocks to watch on Monday, April 8: At around 8:06 am, Gift Nifty futures traded with a gain of 0.26 per cent or 58.5 points at 22,654, suggesting positive opening on the D-Street.

Equity benchmark index Sensex registered marginal gains to hit a fresh lifetime high on Friday after the Reserve Bank of India (RBI) maintained the status quo on key interest rates amid a negative trend in global markets. The six-member rate-setting panel of the Reserve Bank of India (RBI) on Friday kept the benchmark interest rates unchanged at 6.5 per cent for the seventh time in a row. 


The 30-share BSE Sensex inched up 20.59 points or 0.03 per cent to settle at a fresh record closing high of 74,248.22. 

The broader NSE Nifty ended with a marginal loss of 0.95 points at 22,513.70. As many as 28 components of the 50-share benchmark ended in red.

Here are some stocks that will be in focus on Monday, April 8: 

Wipro: The company informed about the exit of Thierry Delaporte who after a significant tenure at the company will be replaced by the new Srini Pallia, appointed as the Chief Executive Officer and Managing Director of the Company, effective immediately.

BPCL: The company during the year 2023-24 recorded the highest-ever market sales of 50.95 MMT.

Godrej Consumer Products: The company said it expects to deliver underlying volume growth of high single digits and sales growth of mid-single digits, driven largely by currency volatility at a consolidated level (organic). 

Paytm: Paytm parent One97 Communication approves a grant of 91,250 stock options. 

Aurobindo Pharma: The United States Food and Drug Administration (USFDA) inspected a new injectable facility of Eugia Steriles Private Limited situated in Andhra Pradesh. The inspection closed with three observations.

GE Power: The company received a purchase order worth Rs 10.1 crore from Mangalore Refinery and Petrochemicals Limited.

Titan: The company posted good growth in revenue of 17 per cent YoY, with CaratLane leading the company’s growth at 30 per cent sales growth. 

Tata Steel: The company in its Q4 business update said that production at the company soared a tad 1.7 per cent during the March quarter of FY24.

Voltas: In the previous fiscal year, volume at the company logged a healthy growth of 35 per cent on year amid a good quantum of sales of AC units. This is a magnificent milestone achieved by the company as no consumer durable company in any fiscal year has logged such huge sales.

Nestle: There has been approved to increase royalty payments to the company’s Swiss parent Société des Produits Nestlé S.A. Nestlé S.A. in the next 5 years will increase its payout to 5.25% from the current 4.5% per annum.

GCPL: The FMCG company in its Q4 business update said that on a consolidated level, the company posted high single-digit growth in volume during the period. The company’s Indonesian business is logging double digit growth in volume and revenue.

Aurobindo Pharma: The US FDA has inspected the company’s subsidiary and issued three observations post-conclusion of the investigation.

Strides Pharma: At the company’s subsidiary’s formulation facility, the USFDA after a regular GMP exercise has issued two observations.

InfoEdge:  The company has released an update for the standalone billing, which during the last March ended quarter registered 10.5 per cent on year growth to Rs 826.9 crore

Chola Investment: The disbursement at the NBFC company logged a high double-digit growth during the March ended quarter. AUM at the company has also logged a good 55 per cent jump. 

PNB: In its Q4 business update, the bank informed that advances at the company grew 11.5 per cent on year, while deposits grew 7 per cent on year.

Bank of Baroda: At the lender, retail advances during Q4, posted a healthy on year growth of 20.64 per cent. 

(With inputs from agencies.) 

Catch the latest stock market updates here. For all other news related to business, politics, tech and auto, visit

Source link


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button